Satellos Bioscience Inc
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy di… Read more
Satellos Bioscience Inc (MSCLF) - Total Liabilities
Latest total liabilities as of September 2025: $3.50 Million USD
Based on the latest financial reports, Satellos Bioscience Inc (MSCLF) has total liabilities worth $3.50 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Satellos Bioscience Inc - Total Liabilities Trend (2020–2024)
This chart illustrates how Satellos Bioscience Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Satellos Bioscience Inc Competitors by Total Liabilities
The table below lists competitors of Satellos Bioscience Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Koryx Copper Inc.
OTCQB:KRYXF
|
USA | $12.45 Million |
|
Dongwha Pharm.Co.Ltd
KO:000020
|
Korea | ₩252.51 Billion |
|
AAPICO Hitech Public Company Limited
BK:AH
|
Thailand | ฿12.04 Billion |
|
Yuan High-Tech Development Co Ltd
TWO:5474
|
Taiwan | NT$671.22 Million |
|
Pacific Century Regional Developments Limited
F:PFQ
|
Germany | €412.05 Million |
|
Summit State Bank
NASDAQ:SSBI
|
USA | $903.41 Million |
|
Malayan Flour Mills Bhd
KLSE:3662
|
Malaysia | RM922.77 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down Satellos Bioscience Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.70 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.10 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Satellos Bioscience Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Satellos Bioscience Inc (2020–2024)
The table below shows the annual total liabilities of Satellos Bioscience Inc from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.59 Million | +31.48% |
| 2023-12-31 | $2.73 Million | -3.47% |
| 2022-12-31 | $2.83 Million | +34.51% |
| 2021-12-31 | $2.10 Million | +60.21% |
| 2020-12-31 | $1.31 Million | -- |